As of close of business last night, Syndax Pharmaceuticals Inc’s stock clocked out at $23.76, down -0.42% from its previous closing price of $23.86. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 1075839 shares were traded. SNDX stock price reached its highest trading level at $24.20 during the session, while it also had its lowest trading level at $23.08.
Ratios:
To gain a deeper understanding of SNDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.00 and its Current Ratio is at 10.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Scotiabank on January 31, 2024, Downgraded its rating to Sector Perform and sets its target price to $23 from $36 previously.
On December 22, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $45.
On October 25, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.BofA Securities initiated its Buy rating on October 25, 2023, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 09 ’23 when Morrison Briggs sold 52,855 shares for $18.27 per share. The transaction valued at 965,402 led to the insider holds 17,836 shares of the business.
Meury William sold 83,000 shares of SNDX for $1,697,810 on Aug 02 ’23. The Director now owns 48,000 shares after completing the transaction at $20.46 per share. On Jul 10 ’23, another insider, Morrison Briggs, who serves as the Director of the company, sold 52,855 shares for $20.40 each. As a result, the insider received 1,078,068 and left with 17,836 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 2.02B and an Enterprise Value of 1.44B. Its current Enterprise Value per Revenue stands at 7.85 whereas that against EBITDA is -6.90.
Stock Price History:
Over the past 52 weeks, SNDX has reached a high of $25.34, while it has fallen to a 52-week low of $11.22. The 50-Day Moving Average of the stock is 22.22, while the 200-Day Moving Average is calculated to be 18.87.
Shares Statistics:
It appears that SNDX traded 1.37M shares on average per day over the past three months and 1.18M shares per day over the past ten days. A total of 84.83M shares are outstanding, with a floating share count of 80.62M. Insiders hold about 5.11% of the company’s shares, while institutions hold 100.39% stake in the company. Shares short for SNDX as of Feb 29, 2024 were 9.09M with a Short Ratio of 6.65, compared to 8.69M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.70% and a Short% of Float of 13.21%.
Earnings Estimates
As of right now, 10 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.99 for the current quarter, with a high estimate of -$0.91 and a low estimate of -$1.11, while EPS last year was -$0.59. The consensus estimate for the next quarter is -$1.04, with high estimates of -$0.95 and low estimates of -$1.21.
Analysts are recommending an EPS of between -$3.24 and -$4.85 for the fiscal current year, implying an average EPS of -$3.87. EPS for the following year is -$2.89, with 11 analysts recommending between -$1.06 and -$3.74.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $129.01M in the next fiscal year. The high estimate is $278.08M and the low estimate is $71.05M. The average revenue growth estimate for next year is up 337.80% from the average revenue estimate for this year.
